The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)  by Lee, B.Y. et al.
The economic burden of community-associated methicillin-resistant
Staphylococcus aureus (CA-MRSA)
B. Y. Lee1, A. Singh1, M. Z. David2, S. M. Bartsch1, R. B. Slayton1, S. S. Huang3, S. M. Zimmer1, M. A. Potter1, C. M. Macal4,
D. S. Lauderdale2, L. G. Miller5 and R. S. Daum2
1) University of Pittsburgh, Pittsburgh, PA, USA, 2) University of Chicago, Chicago, IL, USA, 3) University of California, Irvine, CA, USA, 4) Argonne National
Laboratory, Chicago, IL, USA and 5) Los Angeles Biomedical Research Center at Harbor-UCLA Medical Center, Torrance, CA, USA
Abstract
The economic impact of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) remains unclear. We developed an
economic simulation model to quantify the costs associated with CA-MRSA infection from the societal and third-party payer perspec-
tives. A single CA-MRSA case costs third-party payers $2277–$3200 and society $7070–$20 489, depending on patient age. In the Uni-
ted States (US), CA-MRSA imposes an annual burden of $478 million to 2.2 billion on third-party payers and $1.4–13.8 billion on
society, depending on the CA-MRSA definitions and incidences. The US jail system and Army may be experiencing annual total costs of
$7–11 million ($6–10 million direct medical costs) and $15–36 million ($14–32 million direct costs), respectively. Hospitalization rates
and mortality are important cost drivers. CA-MRSA confers a substantial economic burden on third-party payers and society, with CA-
MRSA-attributable productivity losses being major contributors to the total societal economic burden. Although decreasing transmission
and infection incidence would decrease costs, even if transmission were to continue at present levels, early identification and appropri-
ate treatment of CA-MRSA infections before they progress could save considerable costs.
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Introduction
Studies have suggested that community-associated methicil-
lin-resistant Staphylococcus aureus (CA-MRSA, i.e. MRSA colo-
nization and infection not associated with healthcare
settings) is a substantial public health problem [1,2]. CA-
MRSA strains are common causes of skin and soft tissue
infections (SSTIs) in the United States (US) [3,4], with
reported outbreaks in many diverse settings and populations,
including prisoners, military recruits, and athletes [5,6]. CA-
MRSA strains have become endemic [7,8], predominantly
causing SSTIs but also necrotizing pneumonia and invasive
syndromes such as necrotizing fasciitis, osteomyelitis, septic
thrombophlebitis, bacteraemia, and severe sepsis [6]. While
studies have shown increases in CA-MRSA infection inci-
dence among veterans [9] and CA-MRSA SSTI incidence
[10], its overall incidence in the US has not been clearly
delineated. Although the Centers for Disease Control and
Prevention (CDC) have initiated CA-MRSA public awareness
campaigns [11], there is a dearth of documented community-
level efforts to curb transmission.
An extensive literature search for economic studies on
CA-MRSA yielded only two, one quantifying the cost impact
of an epidemic on Driscoll Children’s health plan [12] and
another focusing on just pneumonia patients [13]. Until CA-
MRSA’s overall economic burden is better quantified, it may
be difficult for decision makers to determine where CA-
MRSA should fall on public health, medical, and scientific pri-
ority lists. Without an estimate of the costs associated with
CA-MRSA infections, many questions remain. For example,
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how much should policy makers invest in prevention, educa-
tion and control? Should insurance companies focus efforts
and reimbursement policies on prevention and control? How
much should be invested in developing new diagnostic, pre-
vention and treatment interventions? Therefore, we devel-
oped an economic computational model to quantify the
costs associated with CA-MRSA infection from the third-
party payer and societal perspectives.
Methods
Model structure
Fig. 1 outlines the structure of our economic simulation
model developed in TreeAge Pro 2009 (Williamstown, MA,
USA) to determine the costs associated with a CA-MRSA
infection from third-party payer and societal perspectives.
Table 1 displays the model inputs. To obtain these values, we
conducted an extensive Medline search using key words
(‘Methicillin-Resistant Staphylococcus aureus’, ‘Staphylococcus
aureus’, ‘Methicillin Resistance’, ‘Community-Acquired Infec-
tions’, and ‘CA-MRSA’) to identify studies and excluded those
conducted outside the US or among immunocompromised
populations. Our study used the CDC epidemiological defini-
tion of CA-MRSA to determine each infection type probabil-
ity. An infection was considered CA-MRSA if the culture was
obtained during an outpatient visit or within 48 h of hospital
admission. Also within the past year, the patient must not
have been admitted to a hospital, nursing home or any other
long-term care facility and not have haemodialysis or surgery.
Furthermore, an indwelling catheter or a percutaneous device
must not have been in place at the time of culture [6].
Every individual entering the model had a CA-MRSA infec-
tion, having one of three major clinical categories (90% of
all types): SSTI (non-purulent cellulitis, impetigo, folliculitis,
uncomplicated purulent cellulitis or complicated SSTI), pneu-
monia, or other invasive infection (infection of a normally
sterile body site, mostly bacteraemia). Some subjects with
SSTIs sought medical care and those who did not relied on
self-medication with over-the-counter NeosporinTM (neomy-
cin, polymyxin B sulphate and bacitracin) ointment. SST
patients who sought care were treated in an outpatient
clinic, emergency room (ER), or hospital. All patients with
pneumonia or other invasive infection required hospitaliza-
tion. When probabilities did not sum to one, a Dirchilet dis-
tribution was used to normalize the probabilities.
The Infectious Diseases Society of America (IDSA) guide-
lines and expert opinion guided the treatment regimen for
each syndrome [14]:
• Non-purulent cellulitis (outpatient): 5–10-day course of
trimethoprim-sulphamethoxazole (TMP-SMX)
• Impetigo (outpatient): 2% topical mupirocin ointment
twice a day for 2 weeks
• Folliculitis (outpatient): warm-water packs/presses (no
cost)
• Uncomplicated purulent cellulitis (outpatient): incision
and drainage (I&D) with or without TMP-SMX
• Complicated SSTI (hospitalized): intravenous (IV) vanco-
mycin (dosed by age and weight), switched to a 5–10-day
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FIG. 1. General structure of the decision model.
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TABLE 1. Model input parameters
Parameter
Distribution
typea Mean/Median
Standard deviation
(SD) or range
Skin and soft tissue infection (SSTI; includes non-purulent cellulitis, impetigo, folliculitis, uncomplicated purulent cellulitis and complicated SSTI)
Probabilities
Having an SSTI b 0.78 0.0004
Incision and drainage in ambulatory settings for purulent
cellulitis (adult)
0.83
Incision and drainage in ambulatory settings for purulent and
non-purulent cellulitis (paediatric)
0.144
Incision and drainage in hospital with purulent cellulitis (adult) 0.98
Incision and drainage in hospital for purulent and non-purulent cellulitis (paediatric) 0.478
Healthcare utilization if seeking medical care
Outpatient facility visit 0.738
Emergency room (ER) visit 0.205
Hospitalization after outpatient visit 0.021
Hospitalization after ER visit D 0.136 0.105–0.147
Hospital (adult) 0.057
Hospital (paediatric) 0.25
In-hospital mortality (adult) 0.001
In-hospital mortality (paediatric) 0
Costs (US$)
Hospitalization (<1 year old)b c 3891.2 137.68
Hospitalization (1–17 years old)b c 3891.2 120.2
Hospitalization (18–44 years old)b c 5842.57 88.76
Hospitalization (45–64 years old)b c 7252.78 113.89
Hospitalization (65–84 years old)b c 7708.01 140.02
Hospitalization (85 years old and over)b c 7053.17 138.29
Incision and drainage in ERb c 389.67 228.62
Incision and drainage in outpatient settingsb c 396.07 159.88
Debridement cost in facilityb c 436.14 333.29
Neosporin c 6.01 1.84
2% Mupirocin c 56.86 19.61
Durations
Outpatient/ER visit (hours) 4
Hospitalization (median, days) D 4 3–5
Outpatient length of therapy (days) U 5–10
Inpatient length of therapy (days) U 7–14
Pneumonia
Probabilities
Having pneumonia b 0.053 0.00046
Hospitalization 1.0c
In-hospital mortality (adult) b 0.12 0.088–0.15
In-hospital mortality (paediatric) 0.076
Costs (US$)
Hospitalization (<1 year old)b c 39112.2 6234.91
Hospitalization (1–17 years old)b c 22673.63 5141.96
Hospitalization (18–44 years old)b c 24 384.77 3621.71
Hospitalization (45–64 years old)b c 26 327.53 1896.42
Hospitalization (65–84 years old)b c 20 938.53 864.29
Hospitalization (85 years old and over)b c 17 284.14 901.43
Durations
Hospitalization (adult; days) c 18.2 16.6
Hospitalization (paediatric; median, days) 23.7 6–138
Length of therapy (weeks) U 1–3
Other invasive infections
Probabilities
Having an invasive infection 0.0625
Hospitalization 1.0c
Echocardiogram (paediatric) 0.10–0.20
In-hospital mortality (adult) b 0.1583 0.000231
In-hospital mortality (paediatric) b .0246 0.0240
Costs (US$)
Hospitalization (<1 year old)b c 6581.56 810.71
Hospitalization (1–17 years old)b c 9377.01 890.03
Hospitalization (18–44 years old)b c 13 560.29 921.74
Hospitalization (45–64 years old)b c 14 390.99 787.05
Hospitalization (65–84 years old)b c 13 691.28 550.31
Hospitalization (85 years old and over)b c 10 883.61 349.61
Durations
Hospitalization (adult; days) D 6.0 4–8.5
Hospitalization (paediatric; days) 14.2 7.6
Length of therapy (weeks) U 2–3
General parameters
Costs (US$)
IV insertionb 25.14
Echocardiogramb c 334.31 31.22
Oral TMP-SMXd daily dose c 3.53 0.82
Vancomycin IV daily dose/kg (adult) c 0.42 0.32
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course of TMP-SMX 1 day prior to discharge; almost all
required I&D
• Pneumonia: IV vancomycin during hospitalization,
switched to TMP-SMX 1 day prior to discharge for a
total therapy duration of 1–3 weeks
• Other invasive infections: IV vancomycin during hospital-
ization with 2–3 weeks subsequent home health nursing
with IV vancomycin administration; paediatric patients
could receive an echocardiogram
Selected regimens were conservative (least expensive) and
do not represent all possible regimens recommended by
IDSA Guidelines or used in practice.
The third-party payer perspective included only direct
medical costs (i.e. outpatient/ER visit, hospitalization, and
treatment costs), while the societal perspective included
both direct and indirect (i.e. productivity losses due to work
absenteeism from healthcare visits and hospitalization for
individuals or caregivers if patient £18 years, and mortality)
costs. Median hourly and annual wages for all occupations
served as proxies for productivity losses. Work absenteeism
was calculated as 4 h missed for an outpatient visit and 8 h
per day for the duration of hospitalization (Table 1). Death
resulted in the net present value of lost wages for the
remainder of the person’s life expectancy based on his/her
age [15]. A 3% discount rate adjusted all costs to 2011 US$.
Each simulation fixed a patient’s age, sending 1000 patients
with CA-MRSA infections through the model 1000 times
(1 000 000 total trials). Subsequent simulations systematically
varied patient age (range, <1–85 years).
Study populations
Simulations determined the cost of a single CA-MRSA infec-
tion and an SSTI infection for different patient ages. Multiplying
by the number of cases nationally, these costs-per-case were
extrapolated to the annual national burden. Annual estimates
of US cases came from three studies. Study 1 estimated
94 360 invasive MRSA cases, categorizing 13.7% as commu-
nity-associated using CDC criteria [16]. Assuming 6.25% of all
CA-MRSA infections are invasive [17], there would be
206 837 CA-MRSA infections per year. Study 2 reported an
annual incidence of community-onset MRSA infections (i.e.
occurring among persons not hospitalized in the prior year) of
243 per 100 000 [18]. Extending this nationwide resulted in
720 277 CA-MRSA cases per year. Study 3 reported an inci-
dence of 521 CA-MRSA SSTIs per 100 000 in Chicago (pre-
sented at the IDSA 2011 annual meeting) [19], which would
translate into an estimated 667.9 per 100 000 for all CA-
MRSA infections, resulting in 1 979 869 cases, of which
1 544 298 would be SSTIs. The number of paediatric cases
among the estimates was determined using data reporting
TABLE 1. Continued
Parameter
Distribution
typea Mean/Median
Standard deviation
(SD) or range
Vancomycin IV daily dose/kg (paediatric) c 0.84 0.65
Home healthcare visit 124.63
Hourly wage (median) 16.92
Mortality (median) D 7128.81 5346.61–9295.96
Productivity loss due to mortality (years)
<1 1 080 911
1 1 077 435
5 1 062 460
10 1 041 071
15 1 016 275
20 958 767
35 880 284
50 710 688
65 514 261
85 252 025
Sensitivity analysis
Parameter Baseline Range of Sensitivity Analysis
SSTI patients seeking care 0.30 0.10–0.40
Incision and drainage in ambulatory settings for purulent cellulitis (adult) 0.83 0.65–0.85
SSTI hospitalization (adult) 0.057 0.05–0.45
SSTI hospitalization (paediatric) 0.25 0.05–0.45
References for parameters are listed in Appendix S1.
ab, beta distribution; c, gamma distribution; D, triangular distribution; U, uniform distribution.
bEstimates from online database (as detailed in Appendix S1).
cAs the Infectious Diseases Society of America (IDSA) treatment guidelines recommend vancomycin IV treatment for MRSA pneumonia and invasive patients, they all would
require hospitalization.
dOral TMP-SMX dosage: two double-strength trimethoprim sulphamethoxazole (TMP-SMX) tablets twice daily for adults and 8–12 mg/kg of trimethoprim per day for chil-
dren (individuals <18 years age).
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36.4% [20] and 10.1% [21] of CA-MRSA cases as <18 years
old. These estimates were used to determine a range of costs.
Study 1 represents the lower estimate, as they used the CDC
definition, and Study 3 represents the upper estimate, as they
used a 48-h criterion to define CA-MRSA cases. As SSTIs rep-
resent 75% [22] of infections, we determined their burden
separately using estimates from Study 3 and Study 4, which
reported 164.2 per 100 000 CA-MRSA SSTIs [10].
A similar approach estimated the annual burden for two
particularly high-risk sub-populations: jail (prevalence, 4.5–
79.7% [23]) and military populations (prevalence, £5% [24]).
David et al. [25] evaluated SSTI incidence and aetiology
among detainees at Cook County Jail, reporting 15.84 MRSA
SSTIs per 1000 detainee-years (mean age, 33 years) with a
census of 10 000 detainees at a given time. An army installa-
tion study estimated 35 CA-MRSA SSTI cases per 1000 sol-
diers (mean age, 22 years) [24]. These incidence estimates
multiplied by cost-per-SSTI-case determined the annual eco-
nomic burden in these sub-populations.
Sensitivity analyses
One-way sensitivity analyses systematically varied key param-
eters one at a time throughout their ranges (Table 1). Monte
Carlo probabilistic sensitivity analysis simultaneously varied
all parameters throughout their ranges.
Results
Cost to third-party payers
Table 2 shows the median and 95% range of the total direct
medical costs of a CA-MRSA case from our simulations.
Varying the SSTI care-seeking probability (10–40%) altered
this cost in most cases by <$300 (e.g. median $2698 with a
10% care-seeking probability and $2938 with a 40% probabil-
ity for a 20-year-old). With relatively modest outpatient
costs-per-case (median <$100), hospitalization was the pri-
mary cost-driver.
Cost to society
As Table 2 shows, societal costs were four to seven times
higher than third-party costs, as the vast majority came from
productivity losses (i.e. individuals or caregivers missing work
plus lost productivity from infection-related deaths). Again,
the medical care-seeking probability did not have a substan-
tial impact (increasing by £$500). A child not surviving has
higher productivity losses than an adult; however, we
observe greater productivity losses for adults due to higher
mortality rates.
Costs of a CA-MRSA SSTI
At baseline hospitalization values (5.7% for ‡18 years, 25%
for <18 years), SSTI costs ranged from $202 (<1 year old)
to $326 (65 years) for society and $168 (<1 year old) to
$292 (65 years) for third-party payers. Fig. 2(a) shows how
SSTI costs (societal perspective) trend with age and hospital-
ization rate. Approximately 85–90% of SSTI costs are direct
medical costs. SSTI costs vary by age, this being largely
attributable to adults’ higher mortality. Hospitalization rate
was a much stronger cost-driver among adults than children
(e.g. increasing from 5% to 45% only increased societal costs
by $261 for a 1-year-old, but increased costs by $490 for a
65-year-old).
Fig. 2(b) shows the SSTI cost trend with hospitalization
rate and care-seeking probability for a 23-year-old. The med-
ian cost-per-case when 40% of patients seek care ($370) was
TABLE 2. Median costs (95% rangea) in $US associated with a CA-MRSA case from the societal and third-party payer perspec-
tives
Age
Outpatient
healthcare
costs
Inpatient
healthcare
costs
Total third-party
payer costs
(total direct)b Mortality costsc
Indirect costs
(total productivity
losses)d
Total societal
costs (total direct
and indirect)b
<1 27 (24–32) 3123 (2547–3713) 3200 (2602–3862) 6519 (2172–13 038) 6923 (2570–12 345) 10 212 (5463–15 979)
1 29 (25–37) 2352 (1943–2761) 2373 (2003–2759) 6509 (2168–13 011) 6902 (2565–12 382) 9361 (4848–15 896)
5 33 (26–46) 2410 (2004–2812) 2435 (2060–2850) 6419 (2138–11 769) 6806 (2535–12 145) 9291 (4741–15 814)
10 39 (29–59) 2469 (2099–2918) 2517 (2138–2949) 6290 (2096–11 535) 6679 (2479–11 972) 9270 (4887–15 487)
15 74 (64–83) 2594 (2168–3062) 2635 (2210–3075) 6141 (2046–11 260) 6535 (2449–11 649) 9183 (4908–14 732)
20 73 (65–84) 2787 (2371–3236) 2849 (2458–3328) 17 387 (9660–26 085) 17 418 (10 677–26 067) 20 489 (13 031–28 745)
35 74 (64–84) 2770 (2363–3218) 2861 (2409–3304) 15 976 (9762–23 958) 16 013 (9840–23 925) 19 166 (11 938–27 381)
50 74 (64–84) 2985 (2539–3416) 3068 (2602–3551) 12 921 (7180–19 387) 12 961 (7284–18 695) 16 048 (10 730–22 066)
65 74 (64–84) 2625 (2227–3032) 2711 (2321–3115) 9388 (5216–14 079) 9414 (5298–14 088) 12 200 (8045–16 605)
85 74 (63–83) 2183 (1882–2518) 2277 (1946–2588) 4666 (2593–6750) 4704 (2908–6983) 7070 (4865–9665)
a95% range (as this is a stochastic simulation model in which each input parameter draws from a distribution, each output/result has a distribution).
bTotal third-party payer costs include outpatient/ER visit, hospitalization and treatment costs. Total societal costs include both direct and indirect (i.e. productivity losses due
to work absenteeism from healthcare visits and hospitalization for individuals or caregivers if patient £18 years, and mortality) costs.
cMortality costs include the productivity losses due to mortality and general mortality costs.
dTotal productivity losses include productivity losses due to absenteeism and mortality.
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almost four times higher than when 10% sought care ($97).
The cost more than doubled when hospitalization increased
from 5% to 45%.
Annual burden
Table 3 shows the estimated annual total US and sub-popula-
tion burdens for all CA-MRSA infections and SSTIs. CA-
MRSA yielded average annual US costs of ‡$560 million for
third-party payers. High productivity losses meant societal
costs substantially exceeded third-party costs (‡$2.7 billion).
The estimated annual societal cost to Cook County Jail
was $140 265 (65% of outpatient purulent cellulitis cases
required I&D) and $146 525 when 85% required I&D; annual
direct medical costs ranged from $124 338 to $130 659
(results not shown). Table 3 provides cost estimates for vari-
ous CA-MRSA incidence rates in jails around the country
(748 728 inmates in 2009–2010 [26]).
Estimated annual societal costs to an army installation [24]
ranged from $834 848 (65% of outpatient purulent cellulitis
cases required I&D) to $874 797 (85% required I&D), with
annual direct medical costs ranging from $737 618 to
$780 354 (results not shown). Table 3 shows the annual
costs for all US Army installations.
Discussion
Our study suggests that CA-MRSA confers a substantial eco-
nomic burden, greater than many other acute infectious dis-
eases that have garnered the attention of policy makers,
scientists and manufacturers. For example, the cost per CA-
MRSA infection ($7070–$20 489) is two to five times that of
an influenza case ($3000–$4000 [27]), three to ten times
that of food-borne illness ($1851 [28]) or pertussis ($1952
per case [29]), and over 17 times that of Lyme disease
($397–$923 [30]). Moreover, because the incidence of some
of these diseases is relatively low (e.g. pertussis and Lyme
disease), the annual economic burden of CA-MRSA infections
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is much higher in comparison, 2–13 times higher than per-
tussis (among adults and adolescents) and 8–17 times higher
than Lyme disease. These numbers help justify investment in
effective CA-MRSA prevention and control and imply that
even minimal investment could generate favourable returns
for policy makers, and military and US jail systems. Our
results can also help guide funders and manufacturers in
establishing priorities.
Our results show that CA-MRSA may have hidden costs
that may be missed by certain estimation methods. Because
direct medical costs are only a minority (25%) of the total
cost for all CA-MRSA infections, many hospital and insurance
databases may not capture productivity losses, thus greatly
underestimating costs. Additionally, a substantial proportion
of costs come from the small fraction of deaths. Therefore,
focusing on the majority of cases that carry relatively low
costs (e.g. over-the-counter medications, clinic visits, course
of antibiotics, and perhaps a half-day of lost productivity)
overlooks the impact of complicated cases that rapidly
accrue costs. Appropriate measures could prevent the bulk
of CA-MRSA-associated costs. Reducing transmission and
infection incidence would decrease costs. Even if infection
incidence was to remain at present levels, early identification
and proper treatment of infections before they progress
could save considerable costs.
Therefore, research and policy development could best
proceed concurrently in two directions: (i) developing and
implementing measures to reduce transmission, and (ii) iden-
tifying and treating uncomplicated infections early to ensure
they do not become invasive. These require a better under-
standing of CA-MRSA transmission dynamics and involve
determining who may be at increased risk of disease pro-
gression and more complicated infections. Studies have sug-
gested that crowded environments, lack of hygienic
conditions, sharing contaminated objects (e.g. towels) and
compromised skin integrity lead to increased transmission
[31]. Additionally, individuals with compromised immune sys-
tems, prior antibiotic use or other co-morbidities may be at
higher risk [6,32]. However, much remains unknown. Addi-
tionally, considerable variability remains in antimicrobial man-
agement [14,33]; evolving resistance patterns may further
alter the therapeutic landscape. Considerable debate remains
over the definitions and incidence of CA-MRSA infections.
CA-MRSA infection criteria have varied in the literature,
from the narrower epidemiological criteria of the CDC defi-
nition to broader criteria, such as the 48-hour criterion,
which classifies CA-MRSA infections diagnosed among inpa-
tients cultured within 48 h of admission to a hospital and all
outpatients, with the broader definition leading to a higher
estimated incidence [20]. Since our study demonstrates that
annual US burden is rather sensitive to such definitions,
future studies should clearly state the definition criteria used.
Despite the variability in costs, our study describes the gen-
eral magnitude of the problem (i.e. CA-MRSA at least costs
several billion dollars, perhaps much more, to society and at
least half a billion to third-party payers). Getting a consensus
definition of CA-MRSA and obtaining better infection inci-
dence data would further hone this cost estimate.
Limitations
All models, by definition, are simplifications of real life and
cannot include every possible CA-MRSA infection outcome
[34]. Our model’s parameter values came from studies with
varying rigor and study populations (which may not be com-
parable) and may change as new studies emerge. For simplic-
ity, we divided infections into discrete syndromic categories,
while infections may involve multiple categories or other
severe manifestations.
Endeavouring to be conservative (e.g. using the least
expensive treatment options and the CDC definition) is
likely to underestimate CA-MRSA’s economic burden. Also,
our productivity loss calculations assumed a 40-h work
week, missed work only during outpatient visits or hospital-
ization, and did not account for decreased productivity while
recovering. Our model did not account for all possible pro-
TABLE 3. Annual costs (in $US millions) associated with
CA-MRSA infections and SSTIs only in the US and in the
military and jail system sub-populations
Incidence estimate Third-party
payer perspective
Societal perspective
All CA-MRSA infections annual US burden
Study 1
36.4% of cases are
paediatric
560 (478–644) 2685 (1621–3464)
10.1% of cases are
paediatric
562 (469–632) 2961 (1494–3989)
Study 2
36.4% of cases are
paediatric
1951 (1665–2244) 9350 (5646–12 063)
10.1% of cases are
paediatric
1958 (1630–2187) 10 311 (5205–13 892)
Study 3
36.4% of cases are
paediatric
5363 (4577–6169) 25 701 (15 520–33 159)
10.1% of cases are
paediatric
5509 (5159–6011) 28 343 (14 308–38 186)
SSTI annual US burdena
Study 3
521 per 100 000b 343 (259–451) 393 (312–503)
Study 4
164.2 per 100 000b 108 (82–142) 124 (98–159)
Military
15 per 1000b 14 16
25 per 1000b 23 26
35 per 1000 [24] 32 36
Jail system
10 per 1000b 6 7
12 per 1000b 7 8
15.84 per 1000 [25] 10 11
a83% require incision and drainage.
aEstimated incidence.
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cedures (e.g. pleural drainage and video-assisted thoraco-
scopic surgery) and permanent disability (e.g. amputation)
that may result from severe infections. Our model did not
include infection control interventions for CA-MRSA carriers
or in-hospital transmission, or their associated costs.
Conclusions
The considerable economic burden of CA-MRSA infections
may justify further investment in prevention and control.
Much of the overall burden stems from productivity losses.
A substantial proportion comes from a minority of cases
resulting in death. Although decreasing transmission and
infection incidence would decrease costs, early identification
and appropriate treatment of infections before they progress
could save considerable costs. Therefore, research and pol-
icy development may involve developing and implementing
measures to reduce transmission, identify infections early,
and prevent minor infections from progressing. Although
decision makers may have been aware of some of these
issues, quantifying their general magnitude could help moti-
vate, plan for and guide investment in relevant interventions
and overcome the current general dearth of community-level
interventions.
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